Electro-Optical bags $11.5m funding:
This article was originally published in Clinica
Manufacturer of the MelaFind non invasive melanoma diagnosis tool Electro-Optical Sciences (Irvington, New York) has secured $11.5m in a private placement from institutional investors. The funding, invested by Cowen and Company and ThinkEquity Partners, comprised just over 2 million common shares priced at $5.75 per share and around 500,00 common stock warrants that are exercisable at $8.00 for 54 months beginning six months after the closing of the investment. The company will use the proceeds to further the design and development of MelaFind, which emits multiple wavelengths to capture images of suspicious pigmented skin lesions, and extract data which can be analysed to tell physicians whether or not a lesion should be biopsied.
You may also be interested in...
Feature: Public Health England has revealed it is only a week away from approving a COVID-19 antibody test for distribution via Amazon. HBW Insight looks at the race to place the first, government-approved coronavirus home-test on the UK market.
As part of its efforts to preserve patient access to medicines amid the COVID-19 pandemic, Russia is planning to cap drug prices if increases of more than 30% are detected. It will also allow online sales of non-prescription drugs and may also tighten the rules on fake and substandard products.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.